Suppr超能文献

异基因造血干细胞移植后急性髓系白血病的维持治疗。

Maintenance therapy for AML after allogeneic HCT.

作者信息

Nayak Rahul K, Chen Yi-Bin

机构信息

Department of Medicine, Massachusetts General Hospital, Boston, MA, United States.

Hematopoietic Cell Transplant and Cell Therapy Program, Massachusetts General Hospital, Boston, MA, United States.

出版信息

Front Oncol. 2022 Aug 9;12:895771. doi: 10.3389/fonc.2022.895771. eCollection 2022.

DOI:10.3389/fonc.2022.895771
PMID:36016625
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9397403/
Abstract

Allogeneic hematopoietic cell transplant (allo-HCT) for eligible patients with acute myeloid leukemia (AML) in first complete remission is a central treatment paradigm to achieve durable remission. However, disease relapse after allo-HCT remains a significant concern and generally portends a poor prognosis. There is significant interest regarding the role for maintenance therapy after allo-HCT for patients with high risk of relapse, regardless of the presence of measurable residual disease. While there are currently no therapies approved for maintenance therapy for AML after allo-HCT, there are a number of ongoing investigations examining the role of maintenance therapies that include targeted agents against FLT3-ITD or IDH mutations, hypomethylating agents, immunomodulatory therapies and cellular therapies. In this review, we examine the current landscape and future strategies for maintenance therapy for AML after allo-HCT.

摘要

对于首次完全缓解的急性髓系白血病（AML）合格患者，异基因造血细胞移植（allo-HCT）是实现持久缓解的核心治疗模式。然而，allo-HCT后的疾病复发仍然是一个重大问题，通常预示着预后不良。对于复发风险高的患者，无论是否存在可测量的残留疾病，allo-HCT后维持治疗的作用都备受关注。虽然目前尚无批准用于allo-HCT后AML维持治疗的疗法，但有许多正在进行的研究在探讨维持治疗的作用，这些维持治疗包括针对FLT3-ITD或IDH突变的靶向药物、去甲基化药物、免疫调节疗法和细胞疗法。在本综述中，我们研究了allo-HCT后AML维持治疗的现状和未来策略。

相似文献

1
Maintenance therapy for AML after allogeneic HCT.
Front Oncol. 2022 Aug 9;12:895771. doi: 10.3389/fonc.2022.895771. eCollection 2022.
2
Post-transplant maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation harmonizing multiple therapeutic modalities including targeted therapy, immunotherapy and cellular therapy.
Int J Hematol. 2023 Jul;118(1):1-17. doi: 10.1007/s12185-023-03614-x. Epub 2023 May 22.
3
Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation.
Clin Lymphoma Myeloma Leuk. 2015 May;15(5):298-302. doi: 10.1016/j.clml.2014.12.005. Epub 2014 Dec 12.
4
Treatment of AML Relapse After Allo-HCT.
Front Oncol. 2021 Dec 16;11:812207. doi: 10.3389/fonc.2021.812207. eCollection 2021.
5
Efficacy of a Second Allogeneic Hematopoietic Cell Transplant in Relapsed Acute Myeloid Leukemia: Results of a Systematic Review and Meta-Analysis.
Transplant Cell Ther. 2022 Nov;28(11):767.e1-767.e11. doi: 10.1016/j.jtct.2022.08.008. Epub 2022 Aug 13.
6
Life after transplant: are we becoming high maintenance in AML?
Bone Marrow Transplant. 2016 Nov;51(11):1423-1430. doi: 10.1038/bmt.2016.160. Epub 2016 Jun 20.
7
Sorafenib maintenance in FLT3-ITD mutated AML after allogeneic HCT: a real-world, single-center experience.
Front Oncol. 2024 Jun 24;14:1391743. doi: 10.3389/fonc.2024.1391743. eCollection 2024.
8
Adverse impact of a high allelic burden FLT3-ITD mutation on allogeneic hematopoietic stem cell transplantation in patients with cytogenetically normal AML.
Int J Hematol. 2022 Nov;116(5):731-743. doi: 10.1007/s12185-022-03423-8. Epub 2022 Jul 20.
9
The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Hematology. 2021 Dec;26(1):179-185. doi: 10.1080/16078454.2021.1880753.
10
Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.
Transplant Cell Ther. 2021 Jun;27(6):479.e1-479.e7. doi: 10.1016/j.jtct.2021.02.028. Epub 2021 Feb 25.

引用本文的文献

1
Pre-transplantation levels of lysine (K)-specific methyltransferase 2A () partial tandem duplications can predict relapse of acute myeloid leukemia patients following haploidentical donor hematopoietic stem cell transplantation.
Blood Sci. 2024 Sep 25;6(4):e00207. doi: 10.1097/BS9.0000000000000207. eCollection 2024 Oct.
2
Post-Transplant Maintenance Therapy in Acute Myeloid Leukemia.
Cancers (Basel). 2024 May 26;16(11):2015. doi: 10.3390/cancers16112015.
3
Azacitidine maintenance therapy for blastic plasmacytoid dendritic cell neoplasm allograft: A case report.
World J Clin Cases. 2024 Jan 6;12(1):136-141. doi: 10.12998/wjcc.v12.i1.136.
4
Granulocyte-Macrophage-Colony-Stimulating-Factor Combined with Prostaglandin E1 Create Dendritic Cells of Leukemic Origin from AML Patients' Whole Blood and Whole Bone Marrow That Mediate Antileukemic Processes after Mixed Lymphocyte Culture.
Int J Mol Sci. 2023 Dec 13;24(24):17436. doi: 10.3390/ijms242417436.
5
Immunopathogenic mechanisms and modulatory approaches to graft-versus-host disease prevention in acute myeloid leukaemia.
Best Pract Res Clin Haematol. 2023 Jun;36(2):101475. doi: 10.1016/j.beha.2023.101475. Epub 2023 May 11.
6
The impact of epigenetic modifications on allogeneic hematopoietic stem cell transplantation.
Front Immunol. 2023 May 31;14:1188853. doi: 10.3389/fimmu.2023.1188853. eCollection 2023.

本文引用的文献

1
Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse.
Bone Marrow Transplant. 2023 Aug;58(8):849-854. doi: 10.1038/s41409-023-01987-5. Epub 2023 Apr 25.
2
Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML.
Blood. 2022 Jun 16;139(24):3546-3557. doi: 10.1182/blood.2021014520.
3
Oral hypomethylating agents: beyond convenience in MDS.
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):439-447. doi: 10.1182/hematology.2021000278.
4
GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial.
Blood Adv. 2022 Apr 12;6(7):2183-2194. doi: 10.1182/bloodadvances.2021006255.
5
Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia.
Bone Marrow Transplant. 2022 Feb;57(2):215-223. doi: 10.1038/s41409-021-01515-3. Epub 2021 Nov 8.
6
Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience.
Clin Lymphoma Myeloma Leuk. 2022 Apr;22(4):260-269. doi: 10.1016/j.clml.2021.09.022. Epub 2021 Oct 9.
7
Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation-A Systematic Review and Meta-Analysis.
Transplant Cell Ther. 2021 Dec;27(12):997.e1-997.e11. doi: 10.1016/j.jtct.2021.09.005. Epub 2021 Sep 20.
8
Safety and tolerability of lenalidomide maintenance in post-transplant acute myeloid leukemia and high-risk myelodysplastic syndrome.
Bone Marrow Transplant. 2021 Dec;56(12):2975-2980. doi: 10.1038/s41409-021-01444-1. Epub 2021 Sep 1.
9
Decrease post-transplant relapse using donor-derived expanded NK-cells.
Leukemia. 2022 Jan;36(1):155-164. doi: 10.1038/s41375-021-01349-4. Epub 2021 Jul 26.
10
Phase I Trial of Prophylactic Donor-Derived IL-2-Activated NK Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Sibling Donor.
Cancers (Basel). 2021 May 28;13(11):2673. doi: 10.3390/cancers13112673.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验